Vaccinex Inc

vaccinex.com

No Longer Reporting

The company has not filed an annual or quarterly report since its FY2024 10-K, filed Apr 15, 2025.

The sections below describe the company as of the FY2024 annual report.

What Did They Do?

Develops targeted antibody-based medicines for people with neurodegenerative diseases, cancer and autoimmune disorders.

How Did They Make Money?

Earns revenue from collaboration agreements for research, licensing, development and commercialization, including milestone payments and services performed through its ActivMAb platform.

FY2024 revenue

Who Were Their Customers?

Third-party collaborators enter research and antibody-discovery agreements with Vaccinex; Coherus licensed its CHS-114 antibody candidate.

Did Revenues Turn Into Profits?

No. It lost $18.6M in FY2024.

Operating income, FY2024

−3117% of revenue

▼ −18% (Loss) vs FY2023 (−$22.9M, −4015%)

Net income, FY2024

−3100% of revenue

▼ −8% (Loss) vs FY2023 (−$20.3M, −3553%)

Free cash flow, FY2024

−2699% of revenue

▼ −24% (Loss) vs FY2023 (−$21.4M, −3762%)

How Were They Changing?

Held flat. Revenue was $601K in FY2024, about the same as the $625K of FY2020.

A narrower focus for pepinemab The older report described active development of pepinemab for cancer, Huntington’s disease and Alzheimer’s disease. The latest report focuses on Alzheimer’s disease and says cancer and Huntington’s disease research are paused.

Comments